Canopy Growth Prepares for Investor Pitch as Stock Sinks Below Key Averages Ahead of EBITDA Deadline
Published on 07/21/2026 at 17:54 | Redaktion boerse-global.de
Canopy Growth walks into an investor conference this week with a story to tell, but the market is not yet buying it. Shares of the Canadian cannabis producer have fallen 22.26% on a year-to-date basis, closing at €0.81 on Tuesday after shedding 3.02% in a single session. That leaves the stock more than 16% below its 200-day moving average — a technical signal that the downtrend is well entrenched — and only 8.53% above its 52-week low of €0.75.
CEO Luc Mongeau is set to present the company’s turnaround strategy at the 46th Canaccord Genuity Growth Conference in Boston on August 11 at noon Eastern Time. The presentation will be webcast live and remain accessible for 180 days afterward. The timing is no accident: Canopy is trying to win over institutional investors at a moment when its equity is trading at a fraction of its December 2025 high of €2.00 per share, a decline of 59.46% from that peak.
The bearish chart is hard to ignore. The stock sits below all three major moving averages — the 50-day at €0.8704, the 100-day at €0.8979, and the 200-day at €0.9785 — and the relative strength index of 42.2 offers no clear reversal signal. Still, the six analysts covering the name assign a consensus 'Hold' rating, suggesting that outright panic is absent even as the company burns cash to execute its long-term plan.
Should investors sell immediately? Or is it worth buying Canopy Growth?
That plan rests on two strategic pillars. The first is the March 2026 acquisition of MTL Cannabis, which strengthens Canopy’s position in Canada’s medical market — a segment where it already claims leadership by revenue. Integration of MTL is expected to deliver C$10 million in synergies. The second is the Canopy USA platform, which bundles the acquired brands Wana, Jetty, and Acreage into a vertically integrated beachhead in the US THC market, bypassing the need for federal legalization. Internationally, a relaunch of the Tweed brand in Germany — based on MTL genetics — helped drive a 68% surge in international medical sales in the most recent fiscal quarter.
The overarching target is a positive adjusted EBITDA by fiscal 2027. Management is cutting costs, improving cultivation efficiency, and expanding the brand portfolio to get there. The market is watching the next quarterly report, expected in August 2026, for concrete evidence that Canopy USA is contributing meaningful revenue and that the MTL synergies are materializing. A positive surprise could help close the 6.48% gap to the 50-day moving average.
Risks remain substantial. The DEA’s administrative hearing on rescheduling cannabis to Schedule III, which began in late June 2026, faces opposition from multiple organizations and remains an open regulatory uncertainty. Any adverse outcome or further delay would intensify the financial strain on a company that has yet to prove it can generate sustainable profits. For now, the support at €0.75 is the last line of defense; a break below that level could trigger a new wave of selling. Canopy still has nine months to show investors it can hit its EBITDA target — and this week’s roadshow is the first test of its ability to close the credibility gap.
Ad
Canopy Growth Stock: New Analysis - 21 July
Fresh Canopy Growth information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
